WHO study says remdesivir did not cut hospital stay or mortality in COVID-19 patients

United States News News

WHO study says remdesivir did not cut hospital stay or mortality in COVID-19 patients
United States Latest News,United States Headlines
  • 📰 Reuters
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.

- Gilead Sciences Inc’s remdesivir had little or no effect on COVID-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization has found.

The results are from WHO’s “Solidarity” trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries. “We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Reuters /  🏆 2. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Working in child care does not elevate risk of getting Covid-19, Yale study findsWorking in child care does not elevate risk of getting Covid-19, Yale study findsWorking in child care does not increase the likelihood of adults contracting Covid-19, according to a new academic study from Yale University published Wednesday.
Read more »

Eli Lilly says other COVID-19 antibody drug trials ongoing after study halted for safety concernEli Lilly says other COVID-19 antibody drug trials ongoing after study halted for safety concernEli Lilly & Co on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the treatment in hospitalized COVID-19 patients was paused due to safety concerns.
Read more »

Day-Care Centers Are Very Low Risk for Covid-19 Transmission, Study SaysDay-Care Centers Are Very Low Risk for Covid-19 Transmission, Study SaysChildren in day-care programs present virtually no risk of transmitting Covid-19 to adults, according to a new Yale University study of more than 57,000 U.S. child-care providers.
Read more »

Child care programs not associated with COVID-19 spread, large study findsChild care programs not associated with COVID-19 spread, large study findsA recent study surveyed 57,000 child care providers and found that there was no 'heightened risk' of coronavirus transmission if safety practices were followed.
Read more »

COVID-19 Doesn’t Seem Seasonal, Study SaysCOVID-19 Doesn’t Seem Seasonal, Study SaysNew Studies indicate that the coronavirus that causes COVID-19 seems to be a year-round nuisance, unlike most respiratory viruses, including the flu, which tend to be seasonal.
Read more »



Render Time: 2025-02-25 03:41:59